Donnerstag, 21. Januar 2021
Navigation öffnen
Anzeige:
CAR T Prelaunch
CAR T Prelaunch
 

JOURNAL ONKOLOGIE – STUDIE

NeoADAURA A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

Rekrutierend

NCT-Nummer:
NCT04351555

Studienbeginn:
Dezember 2020

Letztes Update:
08.01.2021

Wirkstoff:
Osimertinib, Cisplatin, Carboplatin, Placebo, Pemetrexed

Indikation (Clinical Trials):
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 3

Sponsor:
AstraZeneca

Collaborator:
-

Studienleiter

Jamie Chaft, MD
Principal Investigator
Memorial Sloan Kettering, USA
Masahiro Tsuboi, MD
Principal Investigator
National Cancer Center Hospital East, Japan
Walter Weder, MD
Principal Investigator
Thoraxchirurgie Bethanien, Switzerland

Kontakt

AstraZeneca Clinical Study Information Center
Kontakt:
Phone: 1-877-240-9479
E-Mail: information.center@astrazeneca.com
» Kontaktdaten anzeigen

Studienlocations (3 von 94)

Research Site
12351 Berlin
(Berlin)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
33611 Bielefeld
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
73730 Esslingen a.N.
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
82131 Gauting
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
06120 Halle
(Sachsen-Anhalt)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
21075 Hamburg
(Hamburg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
69126 Heidelberg
(Baden-Württemberg)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
51109 Köln
(Nordrhein-Westfalen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
26121 Oldenburg
(Niedersachsen)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
97067 Würzburg
(Bayern)
GermanyNoch nicht rekrutierend» Google-Maps
Research Site
4500 Panagyurishte
BulgariaNoch nicht rekrutierend» Google-Maps
Research Site
2540488 Viña del Mar
ChileNoch nicht rekrutierend» Google-Maps
Research Site
673-8558 Akashi-shi
JapanNoch nicht rekrutierend» Google-Maps
Research Site
951-8566 Niigata-shi
JapanNoch nicht rekrutierend» Google-Maps
Research Site
589-8511 Osakasayama-shi
JapanNoch nicht rekrutierend» Google-Maps
Research Site
980-0873 Sendai-shi
JapanNoch nicht rekrutierend» Google-Maps
Research Site
160-0023 Shinjuku-ku
JapanNoch nicht rekrutierend» Google-Maps
Research Site
241-8515 Yokohama-shi
JapanNoch nicht rekrutierend» Google-Maps
Research Site
41404 Daegu
Korea, Republic ofNoch nicht rekrutierend» Google-Maps
Research Site
50612 Gyeongsangnam-do
Korea, Republic ofNoch nicht rekrutierend» Google-Maps
Research Site
58128 Hwasun-Gun
Korea, Republic ofNoch nicht rekrutierend» Google-Maps
Research Site
05030 Seoul
Korea, Republic ofNoch nicht rekrutierend» Google-Maps
Research Site
08308 Seoul
Korea, Republic ofNoch nicht rekrutierend» Google-Maps
Research Site
420029 Kazan
Russian FederationNoch nicht rekrutierend» Google-Maps
Research Site
660133 Krasnoyarsk
Russian FederationNoch nicht rekrutierend» Google-Maps
Research Site
105229 Moscow
Russian FederationNoch nicht rekrutierend» Google-Maps
Research Site
249036 Obninsk
Russian FederationNoch nicht rekrutierend» Google-Maps
Research Site
197022 St. Petersburg
Russian FederationNoch nicht rekrutierend» Google-Maps
Research Site
634063 Tomsk
Russian FederationNoch nicht rekrutierend» Google-Maps
Research Site
CH-8091 Zürich
SwitzerlandNoch nicht rekrutierend» Google-Maps
Research Site
50200 Chiang Mai
ThailandNoch nicht rekrutierend» Google-Maps
Research Site
12120 Pathumthani
ThailandNoch nicht rekrutierend» Google-Maps
Research Site
65000 Phisanulok
ThailandNoch nicht rekrutierend» Google-Maps
Research Site
CH63 4JY Bebington
United KingdomNoch nicht rekrutierend» Google-Maps
Research Site
700000 Ho Chi Minh
VietnamNoch nicht rekrutierend» Google-Maps
Research Site
70000 Ho Chi Minh
VietnamNoch nicht rekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This is a Phase III, randomised, controlled, 3-arm, multi-centre study of neoadjuvant

osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy

alone, for the treatment of patients with resectable EGFRm Non-Small Cell Lung Cancer

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Male or female, at least 18 years of age. For patients aged <20 years and enrolled in

Japan, a written informed consent should be obtained from the patient and his or her

legally acceptable representative

- Histologically or cytologically documented non-squamous NSCLC with completely

resectable (Stage II - IIIB N2) disease (according to Version 8 of the IASLC Cancer

Staging Manual [IASLC Staging Manual in Thoracic Oncology 2016]).

- Complete surgical resection of the primary NSCLC must be deemed achievable, as

assessed by a MDT evaluation (which should include a thoracic surgeon, specialised in

oncologic procedures).

- Eastern Cooperative Oncology Group (ECOG) PS of 0 or 1 at enrolment, with no

deterioration over the previous 2 weeks prior to baseline or day of first dosing

- A tumour which harbours one of the 2 common EGFR mutations known to be associated with

EGFR-TKI sensitivity (Ex19del, L858R), either alone or in combination with other EGFR

mutations (ie, T790M, G719X, Exon20 insertions, S7681 and L861Q).

Exclusion Criteria:

- Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required

steroid treatment, or any evidence of clinically active ILD.

- History of another primary malignancy, except for the following: Malignancy treated

with curative intent and with no known active disease ≥2 years before the first dose

of investigational product (IP) and of low potential risk for recurrence; Adequately

treated non-melanoma skin cancer or lentigo malignancy without evidence of disease;

Adequately treated carcinoma in situ without evidence of disease

- Patients who have pre-operative radiotherapy treatment as part of their care plan

- Mixed small cell and NSCLC histology

- Stages I, IIIB N3, IIIC, IVA, and IVB NSCLC

- T4 tumours infiltrating the aorta, the oesophagus and/or the heart; and/or any bulky

N2 disease

- Patients who are candidates to undergo only segmentectomies or wedge resections

- Prior treatment with any systemic anti-cancer therapy for NSCLC including

chemotherapy, biologic therapy, immunotherapy, or any investigational drug

- Prior treatment with EGFR-TKI therapy

- Current use of (or unable to stop use prior to receiving the first dose of study

treatment) medications or herbal supplements known to be strong inducers of cytochrome

P450 (CYP) 3A4 (at least 3 weeks prior)

Studien-Rationale

Primary outcome:

1. Major Pathological Response (MPR) (Time Frame - From date of randomization to an average of 12 weeks after the first dose):
Defined as ≤10% residual cancer cells in the main tumour, as assessed per central pathology laboratory post-surgery



Secondary outcome:

1. Pathological complete response (pCR) (Time Frame - From date of randomization to an average of 12 weeks after the first dose):
Defined as absence of any residual cancer cells in the dissected tumour samples, including the main tumour and lymph nodes, assessed post-surgery

2. Event-free survival (EFS) (Time Frame - Up to approximately 42 months after the last patient is randomized):
An event is defined as documented disease progression that precludes surgery or requires non-protocol therapy; recurrence or a new lesion, local or distant (a new primary malignancy confirmed by pathology is not considered to be an EFS event.); death due to any cause

3. Overall Survival (OS) (Time Frame - Up to approximately 5.5 years after the last patient is randomized):
Patients will be followed up to approximately 5.5 years after they are randomized.

4. Disease free survival (DFS) (Time Frame - From date of randomization up to approximately 42 months after date of resection):
DFS is defined as the time from the date of surgery until the first date of disease recurrence (local or distant) or date of death due to any cause, whichever occurs first.

5. Downstaging (Time Frame - From date of randomization to an average of 12 weeks after the first dose):
Measured using pathologic mediastinal lymph node evaluation

6. Difference between treatment arms in change from baseline in EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 items) (Time Frame - From randomization to 264 weeks post-surgery):
Assess disease-related symptoms, functioning, and global health status/quality-of-life in patients

7. Concordance of EGFRm status between tumour tissue DNA and patient-matched plasma-derived ctDNA (Time Frame - Baseline)

8. Corcordance of EGFR mutation status between the local and central cobas EGFR mutation test results from baseline tumour samples (Time Frame - Baseline)

9. PK plasma concentrations of osimertinib (Time Frame - From the pre-dose of Cycle 2 to post-dose of Cycle 3 (each cycle is 21 days))

10. Difference between treatment arms in change from baseline in EORTC QLQ-LC13 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Lung Cancer 13 items) (Time Frame - From randomization to 264 weeks post-surgery):
Assess lung cancer-associated symptoms and side effects from conventional chemotherapy and radiotherapy

Studien-Arme

  • Placebo Comparator: Arm 1: Placebo with platinum-based chemotherapy
    Placebo plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
  • Experimental: Arm 2: Osimertinib with platinum-based chemotherapy
    Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator) plus investigator's choice of platinum-based standard of care chemotherapy (pemetrexed/carboplatin or pemetrexed/cisplatin)
  • Experimental: Arm 3: Osimertinib monotherapy
    Osimertinib 80 mg QD (Dose may be reduced to 40 mg QD at the discretion of the investigator)

Geprüfte Regime

  • Osimertinib (AZD9291; TAGRISSO):
    Oral
  • Cisplatin:
    Cisplatin (75mg/m2) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles.
  • Carboplatin:
    Carboplatin (AUC5) to be administered with pemetrexed on Day 1 of every 3-week cycle for 3 cycles
  • Placebo:
    Oral
  • Pemetrexed:
    Pemetrexed (500 mg/m2) to be administered with cisplatin or carboplatin on Day 1 of every 3-week cycle for 3 cycles

Quelle: ClinicalTrials.gov


ASH 2020
  • Phase-III-Studie ASCEMBL bei resistenten/intoleranten Patienten mit CML: STAMP-Inhibitor Asciminib deutlich effektiver als TKI Bosutinib
  • Ruxolitinib-resistente/-intolerante MF-Patienten profitieren im klinischen Alltag möglicherweise von einer Rechallenge
  • Real-world-Daten zu PV: Rechtzeitige Umstellung von HU auf Ruxolitinib wirkt möglicherweise Anstieg thromboembolischer Ereignisse entgegen
  • 5-Jahres-Daten der RESPONSE-2-Studie: Überlegenheit von Ruxolitinib gegenüber BAT im Langzeitverlauf bestätigt
  • Phase-I-Studie: Anhaltendes molekulares Ansprechen mit neuem BCR-ABL-Inhibitor Asciminib bei CML-Patienten mit T315I-Resistenzmutation
  • Patienten mit ITP sind emotional erheblich belastet
  • r/r DLBCL: Vielversprechende erste Daten zur CAR-T-Zell-Therapie mit Tisagenlecleucel in Kombination mit Ibrutinib
  • r/r FL: CAR-T-Zell-Therapie mit Tisagenlecleucel wirksam und sicher
  • Myelofibrose: Ruxolitinib-Startdosis von 10 mg 2x tägl. auch bei initial niedriger Thrombozytenzahl sicher anwendbar
  • Phase-III-Studie REACH3: Ruxolitinib bei chronischer steroidrefraktärer oder steroidabhängiger GvHD wirksamer als die beste verfügbare Therapie